Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.

@article{Ollila1998OverviewOM,
  title={Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.},
  author={David W. Ollila and Mark C. Kelley and G. S. Gammon and Donald L. Morton},
  journal={Seminars in surgical oncology},
  year={1998},
  volume={14 4},
  pages={328-36}
}
Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular response to a melanoma vaccine. The challenge of active specific immunotherapy research is to determine which combination of humoral and cellular immune responses optimizes clinical outcome and how to… CONTINUE READING

From This Paper

Topics from this paper.
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…